IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
IGC Pharma, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.24−0.00 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $24.28M
- P/E (TTM)
- –
- Dividend yield
- –
IGC Pharma, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White Labeling Services [Member] | $1.04M | $1.10M | $1.13M | $1.02M | $1.23M | $1.16M | – | – | – | – | – | – | 92.4% | -15.5% |
| Wellness and Lifestyle [Member] | $85.00K | $82.00K | $71.00K | $90.00K | $98.00K | $113.00K | $164.00K | $177.00K | $200.00K | $228.00K | $242.00K | $300.00K | 7.6% | -13.3% |
| Legacy Infrastructure [Member] | – | – | – | – | – | – | $3.00K | $3.00K | $3.00K | $164.00K | $221.00K | $263.00K | – | – |
| Infrastructure Segment [Member] | – | – | – | – | – | $164.00K | – | – | – | – | – | – | – | – |
| Life Sciences Segment [Member] | – | – | – | – | – | $1.27M | – | – | – | – | – | – | – | – |
By region
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | $1.19M | $1.20M | $1.11M | $1.33M | $1.27M | $1.23M | $1.18M | $1.06M | $1.18M | $987.00K | $1.07M | – | – |
| India | – | – | – | – | – | – | – | $3.00K | $3.00K | $164.00K | $221.00K | $263.00K | – | – |
| Colombia | – | – | $0 | $0 | $2.00K | $2.00K | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of IGC Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.